Luke Fischer, MD, PhD

CLINICAL FELLOW
Neurology

Dr. Luke Fischer (he/his) is a neurologist-neuroscientist with an interest in Lewy body disease. He graduated Phi Beta Kappa from Michigan State University with degrees in Philosophy and Biochemistry & Molecular Biology, and he remained there to complete his PhD degree in Neuroscience in the laboratory of Dr. Caryl E. Sortwell as part of a dual-MD/PhD program. As a trainee in the NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research at Michigan State University, his focus was on the use of deep brain stimulation in rodent models of Parkinson's disease to investigate its potential as a neuroprotective therapy. He remained in her laboratory as a postdoctoral fellow to examine the impact of common genetic variants on clinical outcomes for developing precision medicine approaches for treating patients with Parkinson's disease. He completed his neurology residency at the University of Alabama at Birmingham where he was elected to AOA and served as Chief Resident. As a NINDS R25 resident trainee in the laboratory of Dr. Laura Volpicelli-Daley, he applied confocal and expansion microscopy techniques to human postmortem brain samples to examine co-pathology. Dr. Fischer completed his clinical fellowship in Behavioral Neurology at the University of California San Francisco Memory and Aging Center and remained there for his NINDS UE5 research fellowship in the laboratory of Dr. Lea Grinberg.

ORCID (Open Researcher and Contributor ID)

NeuroTree

UCSF Profile

Publications: 

Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort.

Samudra N, Fischer DL, Lenio S, Lario Lago A, Ljubenkov PA, Rojas JC, Seeley WW, Spina S, Staffaroni AM, Tablante J, Wekselman F, Lamoureux J, Concha-Marambio L, Grinberg LT, Boxer AL, VandeVrede L

BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.

Fischer DL, Auinger P, Goudreau JL, Cole-Strauss A, Kieburtz K, Elm JJ, Hacker ML, Charles PD, Lipton JW, Pickut BA, Sortwell CE

The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.

Mercado NM, Stancati JA, Sortwell CE, Mueller RL, Boezwinkle SA, Duffy MF, Fischer DL, Sandoval IM, Manfredsson FP, Collier TJ, Steece-Collier K

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE

Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.

Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Fischer DL, Manfredsson FP, Kemp CJ, Cole-Strauss A, Lipton JW, Duffy MF, Polinski NK, Steece-Collier K, Collier TJ, Gombash SE, Buhlinger DJ, Sortwell CE

Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration.

Fischer DL, Kemp CJ, Cole-Strauss A, Polinski NK, Paumier KL, Lipton JW, Steece-Collier K, Collier TJ, Buhlinger DJ, Sortwell CE

Impact of age and vector construct on striatal and nigral transgene expression.

Polinski NK, Manfredsson FP, Benskey MJ, Fischer DL, Kemp CJ, Steece-Collier K, Sandoval IM, Paumier KL, Sortwell CE

Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.

Fischer DL, Gombash SE, Kemp CJ, Manfredsson FP, Polinski NK, Duffy MF, Sortwell CE

High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine.

Fischer DL, Collier TJ, Cole-Strauss A, Wohlgenant SL, Lipton JW, Steece-Collier K, Manfredsson FP, Kemp CJ, Sortwell CE

Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE